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Abstract
Aims/hypothesis Obesity is a heterogeneous condition com-
prising both individuals who remain metabolically healthy
(MHO) and those who develop metabolic disorders (metabol-
ically unhealthy, MUO). Adipose tissue is also heterogeneous
in that its visceral component is more frequently associated
with metabolic dysfunction than its subcutaneous component.
The development of metabolic disorders is partly mediated by
the NLR family pyrin domain containing-3 (NLRP3)
inflammasome, which increases the secretion of inflammatory
cytokines via activation of caspase-1. We compared the im-
munological profile and NLRP3 activity in adipose tissue
between MUO and MHO individuals.
Methods MHO and MUO phenotypes were defined, respec-
tively, as the absence and the presence of the metabolic
syndrome. Cellular composition and intrinsic inflammasome
activity were investigated by flow cytometry, quantitative RT-
PCR and tissue culture studies in subcutaneous and visceral
adipose tissue from 23 MUO, 21 MHO and nine lean
individuals.
Results We found significant differences between the three
study groups, including an increased secretion of IL-1β, in-
creased expression of IL1B and NLRP3 , increased number of
adipose tissue macrophages and decreased number of regula-
tory T cells in the visceral adipose tissue of MUO patients
compared with MHO and lean participants. In macrophages
derived from visceral adipose tissue, both caspase-1 activity
and IL-1β levels were higher in MUO patients than in MHO
patients. Furthermore, caspase-1 activity was higher in
CD11c+CD206+ adipose tissue macrophages than in
CD11c−CD206+ cells.
Conclusions/interpretation The MUO phenotype seems to be
associated with an increased activation of the NLPR3
inflammasome in macrophages infiltrating visceral adipose
tissue, and a less favourable inflammatory profile compared
with the MHO phenotype.
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ATM Adipose tissue macrophage
HOMA-IR HOMA of insulin resistance
MHO Metabolically healthy obese
MUO Metabolically unhealthy obese
NLR NOD-like receptor
NLRP3 NLR family pyrin domain containing-3
PE Phycoerythrin
PEC5 Phycoerythrin-cyanin 5
PerCP Perdidin chlorophyll protein
SAT Subcutaneous adipose tissue
SVC Stromovascular cell
VAT Visceral adipose tissue
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Obesity is a heterogeneous condition with no direct relation-
ship between body weight and metabolic abnormalities. Ap-
proximately 30% of all obese individuals do not have the
metabolic syndrome and are at lower risk of developing type
2 diabetes and cardiovascular diseases. These individuals are
referred to in the literature as ‘metabolically healthy obese’
(MHO), whereas obese individuals with metabolic abnormal-
ities are termed ‘metabolically unhealthy obese’ (MUO)
[1–5]. Similarly, white adipose tissue is also heterogeneous,
consisting of a peripheral subcutaneous component (subcuta-
neous adipose tissue [SAT]) and a central intra-abdominal
component (visceral adipose tissue [VAT]); these components
differ in phenotypic, physiological and functional characteris-
tics [6, 7]. Although both SAT and VAT are associated with
metabolic risk profile, it is reported that high VAT is more
strongly correlated with the metabolic syndrome than is SAT
[8, 9]. However, excess VAT may be a marker of dysfunction-
al SAT not being able to expand when facing an energy
surplus [7]. Indeed, in addition to the amount and distribution
of fat, subcutaneous adipocyte hypertrophy is an independent
marker of insulin resistance [10] and a predictor of type 2
diabetes [11]. Interestingly, hypertrophic adipocytes have a
reduced lipid-buffering capacity and a more pro-inflammatory
phenotype [12].
Chronic low-grade inflammation is observed among indi-
viduals with visceral obesity and represents a mechanistic link
between obesity, insulin resistance and type 2 diabetes
[13–15]. Local inflammation in VAT is associated with an
infiltration of macrophages [16, 17], which are crucial for
the production of pro-inflammatory cytokines and interfere
with the effects of insulin on peripheral tissues via autocrine or
paracrine signalling pathways [18, 19]. The adipose tissue
macrophages (ATMs) can be classified into a pro-
inflammatory phenotype, termed M1 or ‘classically activated
macrophages’, well correlated with insulin resistance [17,
20–22], and an anti-inflammatory phenotype, termed M2 or
‘alternatively activated macrophages’ [16, 17]. While well
established in mice [16, 17, 21, 22], the existence of M1 and
M2 subsets of ATMs in humans has not been confirmed and
human ATMs subtypes have rather been described with a mix
of M1 and M2 gene expression profile [20]. Lymphocytes
infiltrating adipose tissue might have a role in obesity-induced
inflammation by modifying the number and activity of ATMs
[23–25]. Particularly, regulatory T lymphocytes secrete anti-
inflammatory cytokines, such as IL-10, inhibit macrophage
migration and induce the differentiation of M2-like macro-
phages [19, 21, 23].
Notably, the elevated plasma levels of the pro-inflammatory
cytokines IL-1β and IL-18 observed in obese people were
found to predict the development of type 2 diabetes [26, 27].
Active IL-1β and IL-18 are produced by the cleavage of their
inactive precursors by the protease caspase-1, which is activat-
ed by large multiprotein complexes named inflammasomes
[28]. Inflammasomes are central components of the innate
immune system that respond to pathogen-associated (microbi-
al products) and danger-associated (host-derived signals) mo-
lecular patterns. These patterns are recognised by intracellular
NOD-like receptors (NLRs). The most extensively studied
inflammasome is NLR family pyrin domain containing-3
(NLRP3). When activated, NLRP3 forms a complex with its
adaptor molecule ASC, which in turn promotes the recruitment
of pro-caspase 1 and its cleavage into active caspase-1 [28].
Compelling evidence shows that the NLRP3 inflammasome
has a central role in obesity-induced inflammation and insulin
resistance via these mechanisms [29–31].
The pathogenic effects of VAT might be related to the
upregulated expression and activation of the NLRP3
inflammasome [32]. However, differences in NLRP3
inflammasome activity and immune cell composition in adi-
pose tissue of MHO and MUO individuals remains largely
unexplored. In this comparative study, we assessed whether
the inflammatory profile of VAT was different in MUO indi-
viduals compared with that in MHO individuals and investi-
gated the mechanisms that could contribute to such
differences.
Methods
Participants and tissue sampling We studied 44 obese
(BMI>30 kg/m2) patients (23 MUO and 21 MHO patients)
undergoing laparoscopic bariatric surgery and nine lean
(BMI<25 kg/m2) individuals undergoing laparoscopic ab-
dominal surgery (fundoplication for reflux disease or chole-
cystectomy for gallstone disease). The metabolic syndrome
was defined in accordance with the commonly accepted def-
inition [1]. Participants with three or more of the following
criteria were classified as having the metabolic syndrome: (1)
elevated waist circumference (≥94 cm in men and ≥80 cm in
women); (2) elevated triacylglycerol level (≥1.7 mmol/l); (3)
reduced HDL-cholesterol level (<1.0 mmol/l in men and
<1.3 mmol/l in women); (4) elevated BP (systolic BP
≥130 mmHg and/or diastolic BP ≥85 mmHg); (5) elevated
fasting glucose level (≥5.6 mmol/l). A metabolic syndrome
score (from 0 to 5) was calculated as a function of the number
of criteria shown by each patient. The MHO and MUO
phenotypes were defined respectively as the absence (meta-
bolic syndrome score ≤2) or presence (metabolic syndrome
score >2) of the metabolic syndrome. The MUO group com-
prised eight patients with type 2 diabetes, including four
patients with non-treated newly diagnosed type 2 diabetes
(with maximum HbA1c of 6.6% [49 mmol/mol]) and four
patients with type 2 diabetes treated with insulin. Patients with
inflammatory and malignant diseases or those treated with
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oral glucose-lowering drugs, such as metformin and sulfonyl-
ureas, were excluded. MHO and lean individuals had no
history of cardiovascular, respiratory or metabolic diseases
and did not receive any lipid-lowering, antihypertensive or
glucose-lowering agents. The study protocol was approved by
the ethics Committee of Liège University Hospital, and all
patients provided written informed consent.
Metabolic variables were measured on fasting blood sam-
ples collected before the surgery. The degree of insulin resis-
tance was estimated using the HOMA of insulin resistance
(HOMA-IR) (fasting plasma glucose [mmol/l]×fasting plasma
insulin pmol/l]/156).
Paired samples of SAT (abdominal wall) and VAT (greater
omentum) were harvested during surgery and processed im-
mediately. A portion of the sample was immediately frozen in
liquid nitrogen and stored at −80°C. The remainder was gently
washed in PBS and used directly for tissue culture or
stromovascular cell (SVC) isolation.
Tissue culture Samples of SAT or VAT were individually
placed in culture flasks with supplemented RPMI medium.
Culture supernatant fractions were collected after 22 h, con-
centrated and stored at −20°C (see electronic supplementary
material [ESM] Methods for further details).
Quantitative RT-PCR Total RNA was extracted from frozen
adipose tissue using the RNeasy Lipid Tissue Mini Kit
(Qiagen, Hilden, Germany), treated with DNase and reverse-
transcribed. Quantitative RT-PCR was performed using
SYBER Green reagents in the ABI 7000 Sequence
Detection System (Life Technologies, Carlsbad, CA, USA)
or in the LightCycler 480 Real-Time PCR System (Roche,
Basel, Switzerland) (see ESM Methods for further details).
Results were normalised to HPRT1 and relative mRNA ex-
pression levels were calculated using 2−ΔCt [33]. Primer
sequences are provided in ESM Table 1.
SVC isolation and flow cytometry Adipose tissue samples
were minced with sterile scissors and digested with type I
collagenase (Sigma-Aldrich, St Louis, MO, USA). SVCs
were isolated by successive centrifugations, washes and fil-
tration (see ESM Methods for further details), and then were
stained with saturating amounts of various fluorochrome-
conjugated antibodies from Ebioscience (Vienna, Austria)
(CD45–phycoerythrin-cyanin 5 [PEC5], CD4–eFluor 450,
CD25–phycoerythrin [PE], CD127 biotin and streptavidin–
allophycocyanin [APC]–eFluor 780) or BD Biosciences (San
Jose, CA, USA) (CD3–Horizon v500, CD8–perdidin chloro-
phyll protein [PerCP] and CD14–FITC). Flow cytometry was
performed on a FACSAria flow cytometer (BD Biosciences)
and data were analysed using FacsDiva 6.1.2 (www.
bdbiosciences.com/eu/instruments/software/facsdiva/) and
FlowJo V.10 software (www.flowjo.com/download/). SVC
subpopulations were determined based on sideward scatter
and CD45 and CD14 expression. The ATMs were sorted
from the CD45+CD14+ SVCs with a purity of >90%,
resuspended at a concentration of 50,000 cells in 500 μl of
supplemented RPMI medium and cultured at 37°C. After
48 h, the culture media were collected, centrifuged and
stored at −20°C.
Caspase-1 activity assay SVCs were suspended in 75 μl of
10 μmol/l fluorogenic caspase-1 substrate (CaspaLux E1-D2;
Euromedex, Strasbourg, France) for 30 min at 37°C. After
washing in PBS supplemented with 3% FBS, cells were
stained with combinations of antibodies from Ebioscience
(CD45-PC5, CD4-eFluor 450) or BD Biosciences (CD14-
APC, CD14-PerCP, CD3-Horizon v500, CD8-PerCP,
CD206-PE and CD11c-APC). Caspase-1 activity was mea-
sured in stained cells on a FACSCanto II flow cytometer (BD
Biosciences) and analysed using FlowJo V.10 software.
ELISA IL-1β and IL-18 proteins were quantified in the cul-
ture media of ATMs or intact SATand VAT by using cytokine-
specific ELISA kits (R&D Systems, Minneapolis, MN, USA)
following the manufacturer’s instructions.
Statistical analysis All results are expressed as the mean ± SE.
GraphPad Prism software v.5 was used for statistical analysis
(www.graphpad.com/scientific-software/prism/). Pairs of
groups were compared by the Mann–Whitney U test.
Correlations were assessed using a Spearman correlation
test. A p value <0.05 was considered statistically significant.
Results
Anthropometric, clinical and biological characteristics of the
study population Clinical and biological details of the patients
are summarised in Table 1. Metabolic variables were similar
among MHO patients and healthy lean participants, as was
arterial BP. Body weight and BMI were similar in the MUO
and MHO group; however, MUO patients had a significantly
increased waist circumference compared with MHO patients.
Both obese groups had significantly higher levels of
C-reactive protein than the lean group had. Compared with
the MHO group, the MUO group had increased levels of
alanine and aspartate transaminases.
The VATof MUO patients is characterised by increased IL-1β
production compared with that of MHO patients IL-1β and
IL-18 levels were measured in the SATand VATof each study
group. Relative to the corresponding SAT, the production of
IL-1β protein was significantly increased in the VATof MUO
patients (Fig. 1a), whereas IL-18 production was increased in
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the VAT of both obese groups (Fig. 1b). The levels of both
cytokines were significantly increased in the VAT of MUO
patients compared with those in the VAT of lean patients
(Fig. 1a, b). IL-1β production was increased fourfold in the
VAT of MUO patients compared with the VAT of MHO
patients (Fig. 1a).
The expression of IL-1β and NLRP3 is upregulated in the VAT
of MUO patients and correlates with the metabolic syndrome
and insulin resistance The production of activated IL-1β
depends on two signals. First, a pro-inflammatory signal
stimulates the transcription of IL1B [28]. A second signal then
induces inflammasome formation and allows caspase-1 acti-
vation and subsequent cleavage of the inactive pro-IL-1β into
active cytokine. In contrast to IL-1β, the regulation of IL-18
biological activity is mainly due to caspase-1 mediated pro-
IL-18 processing [34]. To investigate whether the observed
differences in IL-1β levels were related to differences in the
first signal, IL1B mRNA levels were measured by quantitative
RT-PCR analysis of total RNA samples purified from SATand
VAT. IL18 expression was also determined in these samples.
The observed trends in IL1B expression were similar to
those for cytokine production. The IL1B mRNA level did not
change in the SAT but increased in the VATof both MUO and
MHO patients when compared with the tissues of lean partici-
pants (Fig. 1c). A significant increase in IL1B expression was
found in the VAT of MUO patients compared with that of
MHO patients (Fig. 1c). IL18 mRNA levels were much lower
in the SAT relative to the VAT, regardless of the patient’s
phenotype (Fig. 1d) and did not correlate with the protein
levels detected by ELISA. Indeed, IL-18 production was
increased in the MUO group compared with that in lean
patients (Fig. 1b) despite a decreased IL18 gene expression
(Fig. 1d).
In accordance with these data, we found, in the overall
study population, significant correlations between IL1B or
IL18 expression in VAT and various patient’s characteristics
(Table 2), whereas no significant correlation was found be-
tween the expression of these genes in SATand characteristics
of the patients (data not shown).
NLRP3 expression was increased in the VAT of MUO
patients compared with that of lean andMHO patients, where-
as no difference was observed between lean andMHO partici-
pants (Fig. 2a). Moreover, in the MUO group,NLRP3 mRNA
levels were twofold higher in VAT than in SAT (Fig. 2a). In
the overall study population, positive correlations between the
NLRP3 expression in VAT and patient’s characteristics are
shown in Table 2. ASC (also known as PYCARD) andCASP1
Table 1 Anthropometric, clinical
and biological characteristics of
the participants
Values are means ± SE
The metabolic syndrome is
defined as three or more of
the following: waist Q80 cm in
women and Q94 cm in men, BP
≥130/85 mmHg, fasting glucose
≥5.6 mmol/l, HDL-cholesterol
<1.3 mmol/l in women and 1.0
in men and triacylglycerols
>1.7 mmol/l
*p <0.05 vs lean; † p <0.05
vs MHO
Characteristic Lean MHO MUO
n (male/female sex) 9 (5/4) 21 (3/18) 23 (7/16)
Age (years) 42±4 35±2 42±3
Body weight (kg) 64.1±4 121±4.2* 123.5±5.4*
BMI (kg/m2) 22.7±0.9 42.3±1* 42.7±1.1*
Waist circumference (cm) 73±2.8 115.7±2* 128.7±2.7*,†
Systolic BP (mmHg) 115.1±7.6 123.1±3 135.8±3*,†
Diastolic BP (mmHg) 68.1±5.5 75.5±2 87.1±2*,†
Fasting glucose (mmol/l) 4.9±0.1 4.9±0.1 6.2±0.3*,†
Fasting insulin (pmol/l) 68.40±9.0 116.12±15.9 195.6±30.6*,†
HOMA-IR 2.15±0.27 3.65±0.43 7.77±1.78*,†
HbA1c
HbA1c (%) 5.6±0.07 5.5±0.06 6.2±0.23*
,†
HbA1c (mmol/mol) 37.6±0.69 37.1±0.70 43.8±2.49*
,†
Triacylglycerols (mmol/l) 1.1±0.2 1.2±0.1 1.8±0.2*,†
Total cholesterol (mmol/l) 4.2±0.5 4.5±0.2 4.8±0.2
HDL-cholesterol (mmol/l) 1.1±0.2 1.2±0.1 1.1±0.1
LDL-cholesterol (mmol/l) 2.3±0.3 2.6±0.2 2.8±0.2
Alanine transaminase (μkat/l) 0.46±0.1 0.40±0.1 0.61±0.1†
Aspartate transaminase (μkat//l) 0.39±0.1 0.32±0.1 0.43±0.1†
γ-Glutamyl transpeptidase (μkat/l) 0.40±0.1 0.39±0.1 0.57±0.1
C-reactive protein (nmol/l) 17.4±6.7 63.8±7.6* 80.9±9.5*
Type 2 diabetes (n) 0/9 0/21 8/23
Metabolic syndrome score 0.9±0.3 1.9±0.1* 3.7±0.2*,†
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expression was not significantly affected by obesity or the
metabolic syndrome either in SAT or in VAT (Fig. 2b, c).
Other inflammasomes (NLRP1, NLRC4 andAIM2) were also
investigated. In each study group, NLRP1 mRNA levels were
lower in VAT than in SAT (Fig. 2d). Expression patterns of
NLRC4 and AIM2 were similar in the SAT and VAT of each
group (Fig. 2e, f). The expression of two other NLRs, NOD1
and NOD2 , which are not involved in the inflammasome
pathway but might play a role in the pathophysiology of type
2 diabetes [35, 36], was also similar in the SAT and VAT of
lean and obese participants (ESM Fig. 1).
In summary, IL-1β production in VATwas increased among
MUO patients (Fig. 1a) and was correlated to an upregulated
transcription of IL1B (Fig. 1c) and NLRP3 (Fig. 2a).
The metabolic syndrome is associated with an increased
number of ATMs and a decreased number of regulatory
T cells in VAT As inflammatory cytokines are produced by
macrophages and their production is inhibited by regulatory T
cells [19, 21, 23], we hypothesised that the increased IL1B
and NLRP3 expression in the VAT of MUO patients reflected
variations in the composition of the SVCs. To investigate this
assumption, flow cytometry analyses were performed on
SVCs isolated from SAT and VAT. Anti-CD45 and anti-
CD14 antibodies were used to differentiate ATMs from the
granulocytes, lymphocytes and pre-adipocytes. The number
of these cell types was expressed as a percentage of the total
SVCs (Table 3). The percentage of ATMs was significantly
increased in the VAT of MUO participants compared with
either their SAT or the VAT of MHO and lean participants,
whereas no difference was found between the MHO and the
lean groups. The same pattern was observed for granulocytes.
Unlike ATMs and granulocytes, the percentage of pre-
adipocytes decreased in the VAT of patients with metabolic
abnormalities. Similarly, pre-adipocytes were less numerous
in the VAT than in the SAT of MUO patients. The percentage
of lymphocytes was higher in the VATcompared with the SAT
in both groups of obese patients.
Subsequent flow cytometry analyses on adipose tissue-
derived SVCs were performed to assess the composition of
lymphocyte subpopulations (Table 3). An increased T lym-
phocyte population was observed in the VAT vs the SAT of
obese patients. The percentage of CD8+ T cells was signifi-
cantly increased in the VATof all three study groups compared
with their SAT, whereas the proportion of CD4+ Tcells did not
differ (Table 4). No differences were found between the MHO
and MUO groups in the composition of these T cell popula-
tions. Interestingly, however, a significant reduction in regu-
latory CD4+ T cell percentage was observed in the VAT of
MUO patients compared with either the corresponding SATor
the VAT of MHO and lean participants (Fig. 3a, b).
Table 2 Correlations between characteristics of the study population and







BMI 0.39* −0.09 0.2
Waist circumference 0.5** −0.20 0.5**
Metabolic syndrome score 0.57**** −0.47** 0.39*
Systolic BP 0.33* −0.09 0.12
Diastolic BP 0.39* −0.16 0.19
Fasting glucose 0.56**** −0.27 0.35*
HOMA-IR 0.53** −0.46* 0.65****
HbA1c 0.02 −0.32* 0.12
Triacylglycerols 0.09 −0.30* 0.11
HDL-cholesterol −0.19 0.04 −0.15
LDL-cholesterol 0.17 −0.03 0.02
C-reactive protein 0.42* −0.19 0.44*
Correlations were assessed using a Spearman correlation test
*p <0.05, **p<0.001 and ****p <0.0001Fig. 1 IL-1β and IL-18 protein production and gene expression in the
SATand VATof lean,MHO andMUO participants. (a) IL-1β production
from the SAT and VAT of lean (white circles), MHO (white squares) and
MUO (grey triangles) (n =5, 15 and 15 [including 4 with type 2 diabetes,
white triangles], respectively). (b) IL-18 production from the SAT and
VAT of lean (white circles), MHO (white squares) and MUO (grey
triangles) patients (n =5, 15 and 15 [including 4 with type 2 diabetes,
white triangles], respectively). Intact adipose tissue fragments were cul-
tured for 22 h and cytokine levels were measured in the supernatant
fraction by ELISA. Relative IL1B (c) and IL18 (d) mRNA expression
in the whole SAT and VAT of lean (white circles), MHO (white squares)
andMUO (grey triangles) (n =9, 21, 23 [including 8 with type 2 diabetes,
white triangles], respectively). Total RNA was extracted, and mRNA
levels were measured by quantitative RT-PCR. Data were normalised
according to HPRT1 mRNA levels and presented as a relative value to
that for the VAT of lean participants. The horizontal lines among the data
points represent the means. *p<0.05, **p<0.01, ***p <0.001 (Mann–
Whitney U test)
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These results demonstrate that the VATof MUO patients is
characterised by an ATM and granulocyte infiltration and a
decreased percentage of anti-inflammatory regulatory T cells.
The metabolic syndrome is associated with inflammasome
activation in ATMs isolated from VAT To assess the potential
contribution of immune cells to adipose tissue inflammation,
we examined caspase-1 activity in each subpopulation. SVCs
were incubated with a fluorogenic caspase-1 substrate and
stained for flow cytometry analyses. Subsequently, caspase-1
activity was evaluated with gating on different subpopulations
of SVCs (Fig. 4a–c).
Caspase-1 activity was very low in lymphocytes (Fig. 4a)
and in granulocytes (Fig. 4b) and was not significantly different
between lean, MHO and MUO individuals, either in SATor in
VAT (data not shown). As expected, caspase-1 activity was
elevated in ATMs but the increase was not uniform throughout
the ATM population (Fig. 4c). Indeed, two subsets of ATMs
could be discerned among lean and MHO patients on the basis
of their caspase-1 activity level (Fig. 4c); these subsets were
similarly distributed in the two groups (Fig. 4d). Interestingly,
the proportion of ATMs with high caspase-1 activity was
significantly increased in the VAT of MUO patients (Fig. 4d).
By contrast, no differences were observed between the three
patient groups in the distribution of ATMs in SAT (Fig. 4d).
To further confirm the differences in caspase-1 activity
observed between MHO and MUO patients, the level of
human IL-1β was measured by ELISA in the culture media
of ATMs isolated from the VAT of MHO and MUO patients.
As expected, ATMs isolated from the VAT of MUO patients
produced significantly greater amounts of IL-1β than those
isolated from the VAT of MHO patients (Fig. 4e).
In conclusion, the development of the metabolic syndrome
in obese individuals is associated with inflammasome activa-
tion in ATMs infiltrating VAT, which leads to increases in both
caspase-1 activity and IL-1β secretion.
Activation of caspase-1 is increased in CD11c+CD206+
ATMs Previous studies have shown that ATMs comprise
CD11c+CD206+ cells and CD11c−CD206+ cells [20].
Fig. 2 Expression of inflammasome components in the SAT and VATof
lean, MHO and MUO patients. Relative gene expression of NLRP3 (a),
CASP-1 (b), ASC (c), NLRP1 (d), NLRC4 (e) and AIM2 (f) in the SAT
and VAT of lean (white circles), MHO (white squares) and MUO (grey
triangles) patients (n =9, 21 and 23 [including 8 with type 2 diabetes,
white triangles], respectively). Total RNAwas extracted from the whole
adipose tissue fragment, and quantitative RT-PCR was performed as
described in Methods. Data were normalised according to HPRT1
mRNA levels and presented as a value relative to that for the VATof lean
participants. The horizontal lines among the data points represent the
means. *p <0.05, **p <0.01, ***p <0.001 (Mann–Whitney U test). The
exclusion of the two highest values for NLRP3 expression in the VAT of
MUO does not change the statistical observations
Table 3 Composition of SVCs in
the adipose tissue
Data are presented as % of SVCs
(mean ± SE)
*p <0.05 vs lean (within same tis-
sue); † p <0.05 vs MHO (within
same tissue); ‡ p <0.05 vs SAT
(within same phenotype)
SVC composition SAT VAT
Lean MHO MUO Lean MHO MUO
Macrophages 5.5±1.8 7.5±0.9 7.0±1.1 6.1±1.1 7.9±0.7 10.8±1.2*,†,‡
Granulocytes 7.8±3.7 7.8±2.0 7.6±1.5 3.8±1.1 6.4±1.6 13.0±2.2*,†,‡
Pre-adipocytes 82.0±6.4 78.5±2.7 80.6±2.7 82.6±2.9 74.4±2.3 65.6±2.9*,†,‡
Lymphocytes 4.7±1.6 6.1±0.9 5.4±0.9 8.0±1.9 11.3±1.1‡ 11.7±1.1‡
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CD11c+CD206+ ATMs have a pro-inflammatory profile with
an M1 phenotype, are markers of insulin resistance in human
obesity [20, 37] and secrete more IL-1β than do
CD11c−CD206+ ATMs [20]. As we observed two subsets of
ATMs with different caspase-1 activity levels (Fig. 4c), we
wondered whether these ATM subpopulations corresponded
to CD11c+CD206+ and CD11c–CD206+ ATMs. Caspase-1
activity was measured in CD14+CD11c+CD206+ and
CD14+CD11c–CD206+ ATMs. Regardless of a patient’s body
weight and metabolic abnormalities and the selected adipose
tissue, ATMs with high caspase-1 activity were mainly
CD11c+CD206+, whereas ATMs with low caspase-1 activity
were mainly CD11c–CD206+ (Fig. 5a). Likewise, we showed
that caspase-1 activity was significantly increased in
CD11c+CD206+ ATMs compa red wi th tha t i n
CD11c–CD206+ ATMs in both SAT and VAT (Fig. 5b).
Discussion
This study is the first to compare NLRP3 inflammasome
activity involved in obesity-induced inflammation and insulin
resistance [29–32] and the composition of the SVCs in paired
SAT and VAT samples taken from obese patients with or
without the metabolic syndrome. We describe significant dif-
ferences in the inflammatory profile of VAT from MUO
patients compared with that from MHO patients. First,
NLRP3 and IL1B expression was upregulated in the VAT of
MUO patients compared with that of lean and MHO patients,
providing indirect evidence for the role of the NLRP3
inflammasome in the heterogeneity of obesity. Second, the
VAT of MUO patients was mainly infiltrated by pro-
inflammatory macrophages with an increased caspase-1 ac-
tivity and thus an increased IL-1β release, whereas the VATof
MHO and lean individuals was infiltrated with fewer macro-
phages and these macrophages had a lower caspase-1 activity.
The macrophages with higher and lower caspase-1 activity
were found to correspond mainly to CD11c+CD206+ and
CD11c–CD206+ ATMs, respectively. Finally, the percentage
of anti-inflammatory regulatory T cells was decreased in the
VAT of MUO patients compared with MHO patients. Similar
differences were observed between the VAT and the SAT of
MUO patients. Changes in NLRP3 and IL1B expression,
inflammasome activity and SVCs were not observed in SAT
samples between the three phenotypes.
So the increase in IL-1β production by the VAT of MUO
patients could be explained by a higher number of total ATMs
and an increased part of ATMs with a higher caspase-1
Fig. 3 Decreased number of regulatory T cells in the VAT of MUO
patients. (a ) Representative FACS plots showing CD3+CD4+
CD25+CD127low regulatory T cells from the VAT of MHO and MUO
patients. (b) Gated percentages of regulatory T cells (Treg) among the
CD4+ T cell population from the SAT and VAT of lean (white circles),
MHO (white squares) and MUO (grey triangles) patients (n =7, 15, 19
[including 8 with type 2 diabetes (white triangles)], respectively). The
horizontal lines among the data points represent the means. *p<0.05,
**p <0.01 (Mann–Whitney U test)
Table 4 Composition of the
lymphocyte subsets in the adipose
tissue
Data are means ± SE
*p <0.05 vs SAT within same
phenotype
Lymphocyte composition SAT VAT
Lean MHO MUO Lean MHO MUO
T cells (% of SVCs) 2.6±1.0 4.4±0.7 4.3±0.8 6.3±2.3 9.6±1.2* 9.9±0.9*
CD4 T cells (% of T cells) 58.9±5.0 56.1±2.0 49.9±2.7 45.7±4.8 50.3±2.0 48.2±2.1
CD8 T cells (% of T cells) 25.6±3.3 26.5±1.9 30.2±2.0 41.3±2.8* 36.1±2.1* 36.3±2.3*
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activity. In addition, previous studies have shown that insulin
resistance is associated with an increased pro-inflammatory
CD11c+CD206+ adipose tissue density and CD11c+CD206+/
CD11c−CD206+ ratio in human adipose tissue [20, 37]. How-
ever, because obesity and insulin resistance are also associated
with increased expression and production of other pro-
inflammatory cytokines, such as TNF-α and IL-6, in adipose
tissue [14, 38, 39], this observed increase in IL-1β production
could be also due to a local inflammation in the VATof MUO
patients.
As previously observed [40–42], we found a lower IL18
expression in the VATof MUO patients compared with MHO
and lean participants, whereas their IL-18 secretion was
upregulated. Unlike the expression of IL1Β , the expression
of IL18 is constitutive and not modulated by pro-
inflammatory conditions [34] and the decrease in IL18 mRNA
levels in the VATofMUO patients might reflect differences in
cell composition.
In this study, we did not directly measure visceral fat mass;
only waist circumference was measured, which in itself can-
not discriminate between subcutaneous and visceral obesity.
However, an increased waist circumference combined with
elevated levels of plasma triacylglycerols (a condition called
‘hypertriacylglycerolaemic waist’) is known to be associated
with a very high probability of visceral obesity [43]. Among
MUO participants enrolled in this study, hypertria-
cylglycerolaemic waist was indeed a potent indicator of ex-
cess visceral fat mass. By contrast, MHO patients had normal
plasma triacylglycerol levels and, independently of their body
weight and BMI, had a smaller waist circumference than
MUO patients. Thus, a relative increase in the amount of
VATcould explain the less favourable metabolic profile found
Fig. 4 Increased inflammasome activity in ATMs from the VATofMUO
patients. Representative FACS data of caspase-1 activity. Caspase-1
activity was evaluated by gating (a ) on the granulocyte population
differentiated from the other cells with CD45 staining and sideward
scatter, (b) on the lymphocyte population differentiated from the other
cells with CD14 and CD45 staining and (c) on the ATM population
differentiated from other cells with CD14 and CD45 staining and
extracted from the VAT of lean, MHO and MUO patients. In the lean
and MHO groups, we distinguished two levels of caspase-1 activity,
which indicates that a fraction of the ATMs have lower caspase-1 activity
than the others. (d) The parts of gated ATMs with higher caspase-1
activity in the SAT and VAT of lean (white bars), MHO (grey bars) and
MUO (black bars) participants (n =4, 9, 5 [including 1 with type 2
diabetes], respectively). Data are presented as a value relative to that for
the VATof lean individuals. (e) IL-1β production by the ATMs (50,000
cells/well) isolated from the VAT of MHO (n =6) and MUO (n =9,
including 2 with type 2 diabetes) patients and cultured for 48 h. The
results are shown as the mean ± SE. *p<0.05, **p <0.01 (Mann–Whit-
ney U test)
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among MUO patients. Moreover, we found consistent posi-
tive correlations between waist circumference and the NLRP3
and IL1B gene expression in VAT in the overall study popu-
lation. Some of the findings with regard to the inflammasome
also positively correlate with the metabolic syndrome score,
fasting glucose, HOMA-IR and BP in the whole cohort of
participants. Further research should also be aimed at investi-
gating the immunological profile and inflammasome activity
in other anatomical fat localisations such as the deeper subcu-
taneous, mesenteric and retroperitoneal adipose tissues.
The nature of the stimuli that trigger inflammasome activ-
ity and caspase-1 activation in ATMs, and thereby may cause
the observed differences between MHO and MUO individ-
uals, remains to be determined. Saturated fatty acids can
induce inflammatory cascades in macrophages and adipocytes
through Toll-like receptor 4-dependent effects [44] and
through activation of the NLRP3 inflammasome [45]. In
contrast, unsaturated fatty acids exert strong anti-
inflammatory effects resulting in improved insulin sensitivity
in diet-induced obese mice [46] and do not activate the Toll-
like receptor 4 or the NLRP3 inflammasome [45]. Therefore,
future studies must determine whether fat composition of diets
could partially explain the differences observed in this study.
T lymphocytes accumulate in adipose tissue before macro-
phage populations do and may contribute to metabolic abnor-
malities by controlling their activity [23, 25, 47]. Consistently,
we showed that the number of T lymphocytes, particularly
cytotoxic CD8+ cells, was increased in the VAT compared
Fig. 5 Caspase-1 activity in
CD11c+CD206+ and
CD11c−CD206+ ATMs from SAT
and VAT. (a) Representative
FACS data of ATMs from VATof
lean, MHO and MUO patients,
with high or low caspase-1
activity, stained with CD206 and
CD11c. After adipose tissue
digestion, SVCs were incubated
for 30 min with fluorogenic
caspase-1 substrate and stained
for FACS analysis with
conjugated CD45, CD14, CD11c
and CD206, as described in
Methods. Caspase-1 activity
in ATMs was evaluated by
gating on the ATM population
differentiated from other cells
with CD14 and CD45 staining.
ATMs with high caspase-1
activity were mainly
CD11c+CD206+, whereas ATMs
with lower caspase-1 activity
were mainly CD11c−CD206+. (b)
Differences in caspase-1 activity,
evaluated by median intensity
fluorescence (MFI), in
CD11c−CD206+ (white bars) and
CD11c+CD206+ (grey bars)
ATMs from the SAT and VAT of
all study participants combined
(n =11, including 4 lean, 4 MHO
and 3 MUO patients). The results
are shown as the mean ± SE.
*p <0.05 (Mann–WhitneyU test)
(c) Unstained control ATMs for
CD11c–APC and CD206–PE
Diabetologia
with the SAT in all three patient groups. However, we did not
find any difference between the patient groups in the number
of these cells. Furthermore, the percentage of regulatory
T cells was decreased in the VAT of MUO patients compared
with the corresponding SAT and with the VAT of MHO and
lean participants. Previous studies showed that the number of
regulatory T cells in VAT decreases with obesity in both mice
and humans [23, 25, 37] and that a boost in the number of
these cells can improve insulin sensitivity in diet-induced
obese mice [23]. These cells also induce differentiation of
M2-like macrophages [19, 21, 23]. Therefore, T regulatory
cells may repress adipose tissue inflammation in MHO and
lean individuals. As it has been shown that immunotherapy
using a CD3-specific antibody ameliorates obesity-associated
insulin resistance [25], identifying the mechanisms that lead to
the decrease in regulatory T cells in the VATof MUO patients
might offer therapeutic options [47].
This study has some limitations. First, even though the
number of patients included in the various groups allows us
to observe statistical differences, it remains rather limited.
Second, the MUO study group represents a quite heteroge-
neous population including patients with the metabolic syn-
drome, patients with non-treated type 2 diabetes and patients
with insulin-treated type 2 diabetes. Nevertheless, there was
no significant change in the results when insulin-treated dia-
betic patients were excluded from the MUO group (data not
shown). Third, MHO and MUO phenotypes were defined
based on the absence or presence of the metabolic syndrome.
However, various definitions of MHO and MUO have been
used throughout the literature and there is no standardised
definition of these phenotypes yet [3, 4]. Fourth, the MHO
and MUO groups had not been matched for the sex distribu-
tion. However, there is no difference in gene expression
profile, interleukin production and SVC composition in the
VAT between obese men and women, regardless of our clas-
sification based on the metabolic syndrome score (data not
shown). Finally, a precise assessment of fat distribution (e.g.
quantitative measurement of VAT using an imaging tech-
nique) was not performed in the present study.
In conclusion, this study is the first to demonstrate that the
VAT of MUO individuals has a less favourable inflammatory
profile than that of MHO individuals as a result of the infil-
tration of ATMs with increased caspase-1 activity and IL-1β
production. The inflammasome, and particularly the caspase-
1, might represent a useful therapeutic target in the treatment
and prevention of obesity-induced insulin resistance.
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